Comparative and evolutionary pharmacogenetics of ABCB1: Complex signatures of positive selection on coding and regulatory regions

Pharmacogenetics and Genomics

Volumn 17, Issue 8, 2007, Pages 667-678

  Wang, Haijian ^a   Ding, Keyue ^d   Zhang, Yang ^a   Jin, Li ^a,b   Kullo, Iftikhar J ^d   He, Fuchu ^a,c,e  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^d MAYO CLINIC   (United States)

^e FUDAN UNIVERSITY   (China)

Author keywords

ABCB1; Haplotype; Positive selection; Regulatory variation

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; XENOBIOTIC AGENT;

ARTICLE; COMPARATIVE STUDY; DNA FLANKING REGION; DRUG DISPOSITION; ETHNICITY; EVOLUTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC LINKAGE; GENETICS; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; PHARMACOGENETICS; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

5' FLANKING REGION; ANIMALS; ENVIRONMENT; EVOLUTION, MOLECULAR; GENOME, HUMAN; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; OPEN READING FRAMES; P-GLYCOPROTEIN; PAN TROGLODYTES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; REGULATORY SEQUENCES, NUCLEIC ACID; SELECTION (GENETICS); SEQUENCE ANALYSIS, DNA;

EID: 34447305225     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328165249f     Document Type: Article

References (67)

1. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11:1156-1166.
2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
3. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97:3473-3478.
4. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84:7735-7738.
5. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97:2517-2524.
6. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Takahashi M, et al. Expression of Pglycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297:1137-1143.
7. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62:4955-4962.
8. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348:1442-1448.
9. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
10. Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 2006; 15:797-805.
11. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al. Association between the C3435 T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124:26-33.
12. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1 (C3435 T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13:1847-1854.
13. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
14. Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 2007; 81:265-269.
15. Taniguchi S, Mochida Y, Uchiumi T, Tahira T, Hayashi K, Takagi K, et al. Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther 2003; 2:1351-1359.
16. Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 2004; 311:1179-1187.
17. Wang B, Ngoi S, Wang J, Chong SS, Lee CG. The promoter region of the MDR1 gene is largely invariant, but different single nucleotide polymorphism haplotypes affect MDR1 promoter activity differently in different cell lines. Mol Pharmacol 2006; 70:267-276.
18. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12:437-450.
19. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13:481-494.
20. Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 2004; 13:783-797.
21. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001; 27:234-236.
22. Chu JY, Huang W, Kuang SQ, Wang JM, Xu JJ, Chu ZT, et al. Genetic relationship of populations in China. Proc Natl Acad Sci U S A 1998; 95:11763-11768.
23. Li WH, Ellsworth DL, Krushkal J, Chang BH, Hewett-Emmett D. Rates of nucleotide substitution in primates and rodents and the generation-time effect hypothesis. Mol Phylogenet Evol 1996; 5:182-187.
24. Iyengar S, Seaman M, Deinard AS, Rosenbaum HC, Sirugo G, Castiglione CM, et al. Analyses of cross species polymerase chain reaction products to infer the ancestral state of human polymorphisms. DNA Seq 1998; 8:317-327.
25. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276:14581-14587.
26. Wang H, Hao B, Zhou K, Chen X, Wu S, Zhou G, et al. Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. Ann Hum Genet 2004; 68:563-573.
27. Kent WJ. BLAT: the BLAST-like alignment tool. Genome Res 2002; 12:656-664.
28. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003; 100:9440-9445.
29. Lewontin RC. The detection of linkage disequilibrium in molecular sequence data. Genetics 1995; 140:377-388.
30. Goddard KA, Hopkins PJ, Hall JM, Witte JS. Linkage disequilibrium and allele-frequency distributions for 114 single-nucleotide polymorphisms in five populations. Am J Hum Genet 2000; 66:216-234.
31. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
32. Bandelt HJ, Forster P, Rohl A. Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol 1999; 16:37-48.
33. Akey JM, Zhang G, Zhang K, Jin L, Shriver MD. Interrogating a high-density SNP map for signatures of natural selection. Genome Res 2002; 12:1805-1814.
34. Weir BS, Cockerham CC. Estimating F-statistics for the population structure. Evolution 1984; 38:1358-1370.
35. Sabeti PC, Reich DE, Higgins JM, Levine HZ, Richter DJ, Schaffner SF, et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 2002; 419:832-837.
36. Nei M. Genetic variability in natural populations. In: Tateno Y, Gojobori T, editors. Molecular population genetics and evolution. Amsterdam/New York: Elsevier; 1975.
37. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 1989; 123:585-595.
38. Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, et al. Genetic structure of human populations. Science 2002; 298:2381-2385.
39. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
40. Jin L, Su B. Natives or immigrants: modern human origin in East Asia. Nat Rev Genet 2000; 1:126-133.
41. Di Rienzo A, Hudson RR. An evolutionary framework for common diseases: the ancestral-susceptibility model. Trends Genet 2005; 21:596-601.
42. Bamshad M, Wooding SP. Signatures of natural selection in the human genome. Nat Rev Genet 2003; 4:99-111.
43. Sabeti PC, Schaffner SF, Fry B, Lohmueller J, Varilly P, Shamovsky O, et al. Positive natural selection in the human lineage. Science 2006; 312:1614-1620.
44. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11:217-221.
45. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174.
46. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005; 78:551-558.
47. Lee CG, Tang K, Cheung YB, Wong LP, Tan C, Zhao Y, et al. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet 2004; 41:e60.
48. Tan EK, Chan DK, Ng PW, Woo J, Teo YY, Tang K, et al. Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol 2005; 62:460-464.
49. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 2002; 62:1-6.
50. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genom 2005; 15:693-704.
51. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-528.
52. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 2002; 64:943-948.
53. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003; 22:7496-7511.
54. Kohno K, Sato S, Uchiumi T, Takano H, Kato S, Kuwano M. Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. J Biol Chem 1990; 265:19690-19696.
55. Koyama T, Nakamura T, Komoto C, Sakaeda T, Taniguchi M, Okamura N, et al. MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese. Biol Pharm Bull 2006; 29:1449-1453.
56. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, et al. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 2004; 64:5956-5962.
57. Nebert DW, Dieter MZ. The evolution of drug metabolism. Pharmacology 2000; 61:124-135.
58. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
59. Wooding SP, Watkins WS, Bamshad MJ, Dunn DM, Weiss RB, Jorde LB. DNA sequence variation in a 3.7-kb noncoding sequence 5′ of the CYP1A2 gene: implications for human population history and natural selection. Am J Hum Genet 2002; 71:528-542.
60. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004; 75:1059-1069.
61. Patin E, Barreiro LB, Sabeti PC, Austerlitz F, Luca F, Sajantila A, et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 2006; 78:423-436.
62. Wang Z, Wang B, Tang K, Lee EJ, Chong SS, Lee CG. A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum Mol Genet 2005; 14:2075-2087.
63. Ding K, Kullo IJ. Molecular evolution of 5′ flanking regions of 87 candidate genes for atherosclerotic cardiovascular disease. Genet Epidemiol 2006; 30:557-569.
64. Hahn MW. Detecting natural selection on cis-regulatory DNA. Genetica 2007; 129:7-18.
65. Miki Y, Suzuki T, Tazawa C, Blumberg B, Sasano H. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 2005; 231:75-85.
66. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001; 7:584-590.
67. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 2006; 79:325-338.